Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Large Growth in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large growth in short interest in July. As of July 31st, there was short interest totaling 839,994 shares, a growth of 77.3% from the July 15th total of 473,657 shares. Based on an average daily trading volume, of 24,575,177 shares, the days-to-cover ratio is currently 0.0 days. Approximately 13.7% of the shares of the company are short sold.

Institutional Investors Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC purchased a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent reporting period. 11.77% of the stock is owned by hedge funds and other institutional investors.

Matinas Biopharma Stock Down 1.1%

MTNB traded down $0.00 during midday trading on Tuesday, hitting $0.22. 212,067 shares of the company traded hands, compared to its average volume of 2,145,233. The company’s 50-day moving average is $0.48 and its 200 day moving average is $0.57. The firm has a market capitalization of $1.41 million, a PE ratio of -0.19 and a beta of 1.76. Matinas Biopharma has a 52 week low of $0.21 and a 52 week high of $2.24.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.